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Abstract
Background: We investigated the association of regular dietary intake of L-arginine and both the incidence of
coronary heart disease (CHD) and changes of blood pressure.
Methods: Eligible adults (n = 2284) who participated in the Tehran Lipid and Glucose Study were followed for a
mean of 4.7 years. Dietary intake of L-arginine was assessed at baseline (2006–2008); biochemical variables were
evaluated at baseline and the follow-up examination. Multivariate Cox proportional hazard regression models
adjusted for potential confounders were used to estimate the risk of CHD across tertiles of L-arginine intake. Linear
regression models were also used to indicate the association of L-arginine intake with changes of serum lipids and
blood pressure during the follow-up.
Results: Mean age of participants (42.8 % men) was 38.2 ± 13.4, at baseline. During a mean 4.7 ± 1.4 y of follow-up,
57 participants experienced CHD events. A significant negative association was observed between plant-derived
L-arginine intake and changes of both systolic and diastolic blood pressure, whereas animal-derived L-arginine
intake was related to increased levels of diastolic blood pressure (P < 0.01). Participants in the 2nd tertile (1.45–1.78 g/d)
had a significantly increased risk of CHD events compared to the participants in the 1st tertile (<1.45 g/d) (HR = 1.90,
95 % CI = 1.03–3.58). The risk of CHD had a decreasing trend across increasing plant-derived L-arginine intake (HR = 1.0,
HR = 0.91, 95 % CI = 0.51–1.62, HR = 0.72, 95 % CI = 0.39–1.32, P for trend = 0.03).
Conclusion: Higher intake of plant derived L-arginine may have a protective effect whereas animal-derived L-arginine
may be a risk factor for development of hypertension and CHD events.
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Background
L-Arginine, a conditionally essential amino acid, is the
main substrate of nitric oxide synthase (NOS) family en-
zymes and is responsible for the production of the
endothelium-derived relaxing factor nitric oxide (NO),
which is involved in regulatory mechanisms of the cardio-
vascular system [1, 2]. The body sources of L-arginine in-
clude dietary protein, endogenous synthesis and proteins
turnover; endogenous synthesis of L-arginine in healthy
adults is sufficient, however in some states such human
growth stages, catabolic stress, and dysfunction of the
small intestine or kidney, L-arginine is classified as a con-
ditional amino acid, because under such conditions the
endogenous synthesis of L-arginine is not sufficient to
meet the human body requirement fo L-arginine [3]. Add-
itionally, L-arginine has a number of direct effects on
endothelial functions via antioxidant activity, decrease
blood viscosity, inhibition of angiotensin-converting en-
zyme, stimulation of fibrinolysis, and some hormones
such as glucagon, prolactine and growth hormone [4]. It
has been indicated that any defect in L-arginine metabol-
ism such as increased levels of asymmetric dimethylargi-
nine (ADMA), a competitive inhibitor of NO synthase, are
related to endothelial dysfunction and increased risk of
cardiovascular disease [5].
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It has been proposed that dietary L-arginine intake
may be involved in the development of coronary heart
disease (CHD) via modification of NO homeostasis.
Some previous animal studies and clinical trials however
reported some favorable effects on cardiovascular risk
factors following acute or long-term administration of
L-arginine by several mechanisms, including endothe-
lium dependent vasodilation and inhibition of platelet
aggregation [6–9]. This issue remains a challenging
debate due to some controversial findings [10, 11]; in
CAD patients and postmenopausal women, oral ad-
ministration of 9 g/d L-arginine had no significant ef-
fects on NO production, flow-mediated dilation of the
brachial artery, cell adhesion molecules E-selectin,
intercellular adhesion molecule-1, and vascular cell
adhesion molecule-1 [12, 13].
Some short-term beneficial effects of high-doses
L-arginine supplementation however have been reported
in diseases states, including hypertension and cardiovascu-
lar disease [9], it is not clear whether L-arginine in usual
amount of dietary intake could prevent cardiovascular dis-
ease events. Findings of two previous population-based
studies did not support the cardiovascular protective ef-
fects of regular dietary intake of L-arginine [14, 15].
There is limited data regarding the association of diet-
ary L-arginine and its dietary sources in relation to
CHD, and to the best of our knowledge this issue has
not yet been investigated in the framework of a
population-based prospective examination; such studies
could provide more valuable information regarding
long-term effects of L-arginine intake on cardiovascular
outcomes. Moreover, considering some evidence regard-
ing better utilization of plant-derived L-arginine in the
body [16], the sources of dietary L-arginine may impress
its cardiovascular effects, an issue that should be in-
vestigated in human studies. In this study, we aimed
to evaluate the association of total dietary L-arginine
intake as well as animal- and plant-derived L-arginine




This study was conducted within the framework of the
Tehran Lipid and Glucose Study (TLGS), an ongoing
community-based prospective study being conducted to
investigate and prevent non-communicable diseases in a
representative sample in the district 13 of Tehran, the
capital city of Iran [17]. We recruited 2956 adult men
and women (aged ≥ 19 y), with complete data (demo-
graphics, anthropometrics, biochemicals and dietary
data), who participated in the third TLGS examination
(2006–2008). Participants were excluded from the
final analysis if they had unexplained energy intake
(<800 kcal/d or > 4200 kcal/d) or were on specific di-
ets (n = 567). Participants with cardiovascular disease
history at baseline were also excluded (n = 94). The
remaining participants (n = 2295) were followed until
March 2012, with a mean period of 4.7 years from
the baseline examination. Participants who had left
the study (n = 11) were also excluded and final ana-
lyses was conducted on 2284 adults (977 men, 1307
women) (Fig. 1).
Written informed consents were obtained from all partic-
ipants and the study protocol was approved by the Ethics
Research Council of the Research Institute for Endocrine
Sciences, Shahid Beheshti University of Medical Sciences.
Demographic and anthropometric measures
Demographics, anthropometrics and biochemical mea-
sures were assessed both at baseline (2006–2008) and
again at the follow-up examination (2010–2012). Trained
interviewers collected information including demographic
data, medical history, medication use and smoking habits,
using pretested questionnaires. Weight was measured to
the nearest 100 g using digital scales, while the subjects
were minimally clothed, without shoes. Height was mea-
sured to the nearest 0.5 cm, in a standing position without
shoes, using a tape meter. Body mass index was calculated
as weight (kg) divided by square of the height (m2). Waist
circumference was measured to the nearest 0.1 cm, mid-
way between the lower border of the ribs and the iliac
crest at the widest portion, over light clothing, using a soft
measuring tape, without any pressure to the body. For
blood pressure (BP) measurements, after a 15-minute rest
in the sitting position, two measurements of BP were
taken on the right arm, during a standardized mercury
sphygmomanometer; the mean of the two measurements
was considered as the participant’s BP.
Biochemical measures
Fasting blood samples were taken after 12–14 h from all
study participants at baseline and follow-up phase.
Serum creatinine levels were assayed using kinetic col-
orimetric Jaffe method. Fasting serum glucose (FSG) was
measured by the enzymatic colorimetric method using
glucose oxidase. The standard 2 h serum glucose 2-h SG
test was performed for all individuals who were not on
anti-diabetic drugs. Serum total cholesterol (TC) was
assayed using the enzymatic colorimetric method with
cholesterol esterase and cholesterol oxidase. Triglyceride
(TG) levels were measured by enzymatic colorimetric
analysis with glycerol phosphate oxidase. High-density
lipoprotein cholesterol (HDL-C) was measured after
precipitation of the apolipoprotein B containing lipo-
proteins with phosphotungstic acid. The modified
Friedewald formula was used to calculate LDL-C
levels. Analyses were performed using Pars Azmoon
Bahadoran et al. Nutrition & Metabolism  (2016) 13:23 Page 2 of 9
kits (Pars Azmoon Inc., Tehran, Iran) and a Selectra 2
auto-analyzer (Vital Scientific, Spankeren, Netherlands).
Both inter- and intra-assay coefficients of variation of all
assays were < 5 %.
Serum creatinine levels were assayed using kinetic
colorimetric Jaffe method. To calculate estimated glom-
erular filtration rate (eGFR), the CKD-EPI creatinine
equation, developed by Chronic Kidney Disease
Epidemiology Collaboration, was used. As a single
equation CKD-EPI has been expressed as follows:
eGFR = 141 × min (Scr/κ, 1)
α × max (Scr/κ, 1)
−1.209 ×
0.993age × 1.018 [if female] × 1.159 [if black]. In this
equation, Scr is serum Cr in mg/dL; κ is 0.7 and
0.9 for men and women, respectively, α is −0.329
and −0.411 for men and women, respectively; min
indicates the minimum of Scr/κ or 1, and max indi-
cates maximum of Scr/κ or 1 [18].
Dietary assessment
Dietary assessment was conducted at baseline. A vali-
dated 168-item food frequency questionnaire (FFQ) was
used to assess typical food intake, and total L-arginine
intake as well as L-arginine from animal and plant
sources, over the previous year. L-arginine content of
Fig. 1 Diagram of the study population
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food items (mg/100 g of foods), were multiplied by the
amount of daily intake of food items; dietary total intake
of the participants was estimated by summing up of the
obtained values. To stratify dietary L-arginine sources,
amount of L-arginine intake was separately calculated by
summing up of dietary L-arginine intake from plant
sources (fruits, vegetables, nuts, legumes, grains) and
animal sources (meats, processed meats, dairy, eggs).
The validity of the food frequency questionnaire has
previously been evaluated by comparing food groups
and nutrient values determined from the questionnaire
with values estimated from the average of twelve 24-h
dietary recall surveys [19]. The correlation coefficient for
protein intake between the average of twelve 24-h recalls
and the FFQ was 0.65 and 0.50 in men and women, re-
spectively [19]. Trained dietitians with at least 5 years of
experience in the TLGS survey, asked participants to
designate their intake frequency for each food item con-
sumed during the past year on a daily, weekly, or
monthly basis. Portion sizes of consumed foods reported
in household measures were then converted to grams
[20]. However, since Iranian Food Composition Table is
incomplete, and has limited data on nutrient content of
raw foods and beverages, to analyze foods and beverages
for their energy and nutrient content, we used the US
Department of Agriculture Food Composition Table.
Definition of terms
History of cardiovascular disease was defined as previous
ischemic heart disease and/or cerebrovascular accidents.
Family history of premature cardiovascular disease
reflected any prior diagnosis of cardiovascular disease in
first-degree female relatives aged below 65 years, or first-
degree male relatives aged less than 55 years. Diabetes
was defined as fasting serum glucose ≥ 126, 2 h serum
glucose ≥ 200 or anti-diabetic medications [21]. Current
smoker was defined as a person who smoked cigarettes
daily or occasionally. Chronic kidney disease was defined
as estimated eGFR < 60 mL/min per 1.73 m2 [22]. Dia-
betes was defined as fasting serum glucose ≥ 126, 2 h
serum glucose ≥ 200 or anti-diabetic medications [21].
Definition of outcome in our study
Details of the collection of cardiovascular outcome data
have been described elsewhere [23]. Briefly, each partici-
pant was followed up for any medical event annually by
phone calls. Information of any medical condition or
event was collected by a trained nurse, a trained phys-
ician and by utilization of data from medical files. The
collected data were evaluated and confirmed by an
outcome committee consisting of an internist, an endo-
crinologist, a cardiologist, an epidemiologist and other
experts. In the current study, event was considered as
the first coronary heart disease (CHD) event, including
definite myocardial infarction (MI) [with diagnostic elec-
trocardiogram (ECG) and biomarkers], probable MI
(positive ECG findings plus cardiac symptoms or signs
plus missing biomarkers or positive ECG findings plus
equivocal biomarkers), unstable angina (new cardiac
symptoms or changing symptom patterns and positive
ECG findings with normal biomarkers), angiographic
proven CHD, and death from CHD [24].
Statistical methods
Dietary intake of L-arginine was adjusted for total
energy and protein intake, according to residuals
methods [25]. The mean (SD) values and the fre-
quency (%) of baseline characteristics of the partici-
pants with and without CHD event were compared
using independent t test or chi square test, respect-
ively. Dietary intakes of the participants across tertiles
of dietary L-arginine intakes were compared using the
analysis of variance (ANOVA).
Cox proportional hazard regression was used to assess
the hazard ratios (HRs) of dietary L-arginine intakes for
CHD. Time to event was defined by time of censoring
or having event, whichever came first. We censored par-
ticipants at the time of other causes of death, leaving the
district or being in the study until March 2012 without
event.
A univariate analysis was performed for potential con-
founding variables; variables with PE < 0.2 in the univari-
ate analyses were selected for the final multivariable
models; PE (P value for entry) determines which vari-
ables should be included in the multivariable model.
Linear associations of baseline L-arginine intakes with
both changes of serum lipids and blood pressure during
the follow-up period were estimated using linear regres-
sion models with adjustment of age, sex, energy and pro-
tein intakes.
We assessed dietary intakes of total L-arginine,
plant-derived and animal-derived L-arginine as both
continuous and categorical variables in the models. In
the categorical model, amount of L-arginine and its
subgroups was categorized into tertiles, given the 1st
tertile as reference. In the continuous model, HR was
calculated for each 1 SD increases in the intakes of
L-arginine. Tree Cox proportional hazard regression
models were defined; model 1 were adjusted for age
(y) and sex (male/female); model 2 was further adjusted
for BMI (kg/m2) and smoking status (yes/no); model 3
was additionally adjusted for hypertension (yes/no) and
diabetes mellitus (yes/no). To assess the overall trends of
HRs across tertiles of L-arginine intakes, the median of
each tertile was used as a continuous variable in Cox pro-
portional hazard regression models.
We set the statistical significance level at a two-tailed
type I error of 0.05. All statistical analyses were
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performed using STATA version 12.0 (STATA, College
Station, TX, USA).
Results
Mean age of participants (42.8 % men) was 38.2 ± 13.4,
at baseline. Mean dietary intakes of total L-arginine,
plant-derived and animal-derived L-arginine was 4.0 ± 1.5,
2.2 ± 0.8 and 1.8 ± 0.9 g/d, respectively. Compared to con-
trols, mean intakes of L-arginine was lower in subjects
with CHD (3.8 ± 1.2 vs. 4.1 ± 1.5 g/d, P = 0.05).
During the average of 4.7 ± 1.4 y of follow-up, 57
participants experienced CHD event. The distributions
of the major known CHD risk factors and some bio-
chemical values for the participants who had CHD
event and for those who did not are shown in Table 1.
Risk factors for which there were significant differ-
ences between participants with and without CHD
were age, smoking status, anthropometric measures,
blood pressure, lipid profiles, and serum creatinine.
Higher prevalence of diabetes (14.3 vs. 3.9, P = 0.003)
and HTN (43.9 vs. 8.2, P = 0.001) was observed in
subjects with CHD event compared to the rest of co-
hort. Dietary intakes of the participants across tertiles
of total L-arginine are presented in Table 2. An in-
creasing trend of dietary intakes of total energy,
carbohydrate, cholesterol and protein was observed
across increasing intakes of L-arginine (P = 0.001);
compared to the lowest tertile, those in the highest
tertile of L-arginine had also lower intakes of total fats as
well as saturated and unsaturated fats (P = 0.001).
Table 3 shows linear association of L-arginine intake at
baseline with changes of serum lipids and blood pressure
during the follow-up period. A significant negative asso-
ciation was observed between plant-derived L-arginine
and changes of both systolic and diastolic blood pressure
(β = -1.89, 95 % CI = −4.17, −0.03, and β = −2.78, 95 %
CI = −4.61, −0.92). Animal-derived L-arginine intakes
were related to increased levels of DBP (β = 1.80, 95 %
CI = 0.14, 3.46); total L-arginine intakes were not signifi-
cantly related with changes of serum lipids and blood
pressure.
In the fully-adjusted Cox proportional hazards model,
we observed an increasing trend in the risk of CHD
events across dietary intake of total L-arginine (HR =
1.0, HR = 1.23, 95 % CI = 0.61 − 2.43, and HR = 1.39,
95 % CI = 0.69 − 2.66, P for trend = 0.07) (Table 4).
When animal-derived L-arginine intakes were consid-
ered as exposure in the models, participants in the
2nd tertile (1.45 − 1.78 g/d) had a significantly increased
risk of CHD events compared to the participants in the 1st
tertile (<1.45 g/d) (HR = 1.90, 95 % CI = 1.03 − 3.58),
while highest compared to the lowest intakes (<1.45
vs. ≥1.78 g/d) of animal-derived L-arginine was not re-
lated to the CHD risk (HR = 1.46, 95 % CI = 0.72 − 2.98).
The risk of CHD had a decreasing trend across increasing
plant-derived L-arginine intakes (HR = 1.0, HR = 0.91,
Table 1 Baseline characteristics of the participants
Participants with CHD outcome
(n = 57)
Participants without CHD outcome
(n = 2223)
P value Whole study population
(n = 2280)
Age (y) 59.2 ± 9.7 37.6 ± 13.1 0.001 38.2 ± 13.4
Male (%) 59.6 42.3 0.007 42.8
Smoking (%) 22.8 11.5 0.003 11.7
Body mass index (m2/kg) 28.4 ± 4.4 26.5 ± 4.8 0.004 26.5 ± 4.8
Waist circumference (cm) 97.2 ± 10.1 87.8 ± 13.3 0.001 88.0 ± 13.4
Serum creatinine (μmol/L) 99.5 ± 16.7 91.7 ± 13.5 0.001 91.9 ± 13.7
eGFR (ml/min/1.73 m2) 78.7 ± 13.0 79.8 ± 16.1 0.61 79.8 ± 16.1
Systolic blood pressure (mm Hg) 130 ± 17.4 109 ± 14.9 0.001 110 ± 15.3
Diastolic blood pressure (mm Hg) 80.0 ± 10.6 72.4 ± 10.3 0.001 72.6 ± 10.3
Fasting blood glucose (mg/dL) 106 ± 39.9 88.0 ± 16.6 0.001 88.9 ± 17.7
Total cholesterol (mg/dL) 216 ± 38.0 182 ± 36.8 0.001 183 ± 37.3
Serum triglycerides (mg/dL) 190 ± 107 132 ± 77.0 0.001 133 ± 79.0
LDL-C (mg/dL) 140 ± 31.2 112 ± 31.4 0.001 113 ± 31.6
HDL-C (mg/dL) 40.2 ± 8.0 43.3 ± 10.4 0.025 43.2 ± 10.4
TG/HDL-ratio 5.0 ± 3.1 3.4 ± 2.6 0.001 3.5 ± 2.6
Diabetes (%) 14.3 3.9 0.003 4.2
Hypertension (%) 43.9 8.2 0.001 9.1
Chronic kidney disease (%) 4.4 6.7 0.41 6.7
Data are mean ± SD unless stated otherwise (independent t-test for continuous variables and chi-square test for dichotomous variables was used
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95 % CI = 0.51 − 1.62, HR = 0.72, 95 % CI = 0.39 − 1.32,
P for trend = 0.03), however this negative association
was not statistically significant. Hazard ratios (95 %
CI) of CHD events per 1 SD increased intakes of
total L-arginine, animal- and plant-derived L-arginine
were 1.07 (0.63 − 1.81), 1.12 (0.72 − 1.73), and 0.90
(0.51 − 1.61), respectively.
Discussion
In this prospective cohort study, during 4.7 years of
follow-up of a sample of Iranian adults, some evidence
regarding potential beneficial properties of plant-derived
L-arginine along with adverse effects of animal-derived
L-arginine intakes was observed in relation to cardiovas-
cular risk factors and CHD events; total L-arginine in-
takes had no significant association with CHD risk or
changes of serum lipids and blood pressure. A decreas-
ing trend of CHD risk across increasing dietary intakes
of plant-derived L-arginine, accompanied with a negative
association with changes of systolic and diastolic blood
pressure during the follow-up, may reveal the fact that
plant sources of L-arginine have protective effects
against development of cardiovascular diseases. In con-
trast, our findings indicated an increased risk of CHD
and diastolic blood pressure levels in response to higher
intakes of animal-derived L-arginine; the trend of HRs
across animal-derived L-arginine seems not to be linear.
These observations raised the hypothesis that different
sources of dietary L-arginine may induce different car-
diometabolic consequences.
Limited studies have examined the association of regu-
lar dietary intakes of L-arginine and the risk of cardio-
metabolic disorders. L-arginine intake below the median
range (3.8 g/d) was associated with higher levels of C re-
active protein (CRP); highest level of L-arginine intake
(>7.5 g/d) was also related to 30 % less likely to have a
CRP above 3.0 mg/L [26]. Moreover, a lower prevalence
of elevated SBP and LDL-C was also observed in sub-
jects who consumed >7.5 g/d L-arginine [26]. Favorable
effects of L-arginine supplementation, in doses ranging
Table 2 Dietary intakes of the participants across tertiles of total L-arginine intakes
Total L-arginine intakes
Tertile1 Tertile2 Tertile3 P
Dietary L-arginine (g/d)
Range <3.25 3.25–4.42 ≥4.42
Median 2.65 3.75 5.37
L-arginine from animal sources (g/d) 1.09 ± 0.36 1.69 ± 0.44 2.67 ± 1.1 0.001
L-arginine from plant sources (g/d) 1.47 ± 0.39 2.10 ± 0.45 3.0 ± 0.83 0.001
Energy intake (kcal/d) 1587 ± 365 2217 ± 389 2976 ± 558 0.001
Carbohydrate (% energy) 56.3 ± 7.5 58.0 ± 7.2 57.4 ± 6.6 0.001
Protein (% energy) 11.8 ± 1.6 13.5 ± 1.5 15.6 ± 2.1 0.001
Total fats (% energy) 34.3 ± 7.6 30.9 ± 6.7 29.6 ± 5.7 0.001
Saturated fats (% energy) 11.2 ± 3.3 10.8 ± 7.3 10.1 ± 3.1 0.001
Monounsaturated fats (% energy) 12.0 ± 3.1 10.6 ± 2.7 10.2 ± 2.3 0.001
Polyunsaturated fats (% energy) 7.5 ± 2.6 6.3 ± 2.1 5.8 ± 1.8 0.001
Cholesterol (mg/1000 kcal) 85.0 ± 31.5 99.0 ± 41.0 118 ± 63.7 0.001
Total fiber (g/1000 kcal) 15.7 ± 7.3 16.4 ± 6.8 16.4 ± 5.8 0.06
Data are mean ± SD
Analysis of variance was used
Table 3 Linear association (coefficient β and 95 % CI) of dietary intakes of L-arginine with changes of lipids and blood pressure
during follow-up
Total L-arginine intakes
Total L-arginine Animal-derived L-arginine Plant-derived L-arginine
Systolic blood pressure −0.09 (−2.23, 2.05) 1.48 (−0.05, 3.51) −1.89 (−4.17, −0.03)
Diastolic blood pressure −0.55 (−2.31, 1.21) 1.80 (0.14, 3.46) −2.78 (−4.61, −0.92)
Serum triglycerides 0.42 (−3.66, 4.50) 2.11 (−0.71, 5.95) −2.11 (−6.32, 2.14)
HDL-C 1.62 (−0.08, 3.33) 1.75 (−0.15, 3.37) −0.38 (−2.16, 1.38)
TG/HDL ratio −0.03 (−4.16, 4.09) 1.29 (−2.50, 5.18) −1.60 (−5.88, 2.68)
Linear regression models were used with adjustment of age, sex, energy and protein intakes
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from 4 to 24 g/d, on blood pressure however have con-
firmed in a recent meta-analysis of 11 randomized,
double-blind, placebo-controlled trials [9], hypotensive
effect of regular dietary intakes of L-arginine have not
been investigated in a population-based study.
Oomen et al., based on their findings from a popula-
tion-based cohort study on elderly men, did not
support the hypothesis that dietary L-arginine intake
may lower the risk of CHD mortality; the relative risk
for the medium and high tertiles compared to the
lowest were 1.87 (95 % CI = 1.06 − 3.29) and 1.58
(95 % CI = 0.84 − 2.96), with a non-significant trend
[14]. In this cohort study, a considerable decreasing
trend of serum homosysteine levels were observed
across increasing intakes of dietary L-arginine (13.9
vs. 17.8 μmol/L, P = 0.001, in L-arginine intakes ≥4.65
vs. 0 − 3.85 g/d, respectively); a lower prevalence of
coronary artery disease and diabetes history was also
observed in the highest compared to the lowest
intakes of L-arginine [14]. Lack of stratified analysis
for plant- and animal-derived L-arginine was one of
the more important limitations for interpretation of
these findings, and it is not clear that the association
of L-arginine and CHD mortality to be affected from
which sources of L-arginine.
In a 10-year follow-up of participants of Kuopio
Ischemic Heart Disease Risk Factor Study, Venho
et al. reported that total L-arginine as well as plant-
derived L-arginine intake had no association with
blood pressure or the risk of acute coronary events,
whereas the highest quintile compared to the lowest
quintile of animal-derived L-arginine had a marginally
increased risk of acute coronary event after a 10 year
follow-up (RR = 1.56, 95 % CI = 1.00 − 2.42) [15]; in
this study, the portion of animal-derived L-arginine
was higher than the plant-derived and there was an
increasing trend in animal-derived L-arginine across
quartiles of total intakes of L-arginine [15]. An inter-
esting considerable point of Venho’s study and our
findings was a non-linear trend of CHD risk across
animal-derived L-arginine categorizations; Oomen et al.
also reported similar trend for total L-arginine intake
[14, 15]. Increased risk of CHD in the 2nd tertile of total
L-arginine and 5th quintile of animal-derived L-arginine in
Oomen and Venho cohorts was also comparable with our
finding regarding positive association of animal-derived
L-arginine with the risk of CHD.
Different findings on the association between plant- and
animal-derived sources of L-arginine may be related to
different metabolic response to plant- versus animal-
derived protein [27]. It has been suggested that utilization
of plant-derived L-arginine is better than animal-derived
due to a higher ratio of lysine to L-arginine in animal
proteins; lysine can compete with arginine for intracel-
lular transport, and higher ratio of lysine to L-arginine
may indirectly affect arginine metabolism [16]; there-
fore, it has been suggested that animal and plant
sources of L-arginine induces different physiological
consequence in the body [15].
In our study, a negative association of plant-derived
L-arginine with CHD risk however, was not statisti-
cally significant. Inverse association with changes of
both systolic and diastolic blood pressure may support
speculations regarding cardioprotective effect of plant-
derived L-arginine. Increased NO production have
been reported in hypertension and cardiovascular disease
Table 4 Hazard ratio (95 % CI) of coronary heart disease by tertiles of dietary intakes of L-arginine
Dietary intakes of L-arginine (n = 1237)
1st tertile 2nd tertile 3rd tertile 1 SD increased intakes
Total L-arginine (g/d) <3.25 3.25–4.42 ≥4.42
Adjustment for age and sex Ref. 1.16 (0.59–2.29) 1.33 (0.69–2.59) -
Multivariate model 1 Ref. 1.22 (0.61–2.41) 1.37 (0.68–2.60) -
Multivariate model 2 Ref. 1.23 (0.61–2.43) 1.39 (0.69–2.66) 1.07 (0.63–1.81)
L-arginine from animal sources (g/d) <1.45 1.45–1.78 ≥1.87
Adjustment for age and sex Ref. 1.87 (1.01–3.48) 1.32 (0.65–2.66) -
Multivariate model 1 Ref. 1.85 (0.99–3.45) 1.29 (0.64–2.60) -
Multivariate model 2 Ref. 1.90 (1.03–3.58) 1.46 (0.72–2.98) 1.12 (0.72–1.73)
L-arginine from plant sources (g/d) <1.85 1.85–2.20 ≥2.20
Adjustment for age and sex Ref. 1.21 (0.62–2.35) 0.97 (0.50–1.89) -
Multivariate model 1 Ref. 1.20 (0.61–2.38) 0.97 (0.48–1.92) –
Multivariate model 2 Ref. 0.91 (0.51–1.62) 0.72 (0.39–1.32) 0.90 (0.51–1.61)
Cox proportional hazard regression models were used
Model 1: Additionally adjusted for BMI (kg/m2) and smoking status (yes/no)
Model 2: Additionally adjusted for hypertension (yes/no) and diabetes mellitus (yes/no)
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[28–31]. Although current literature is rather confusing, it
is suggested that overproduction of NO in these states is
mainly due to increased inducible nitric oxide synthase
(iNOS) activity [32]. Nitric oxide overproduction, as a
compensatory response, has also been attributed to
cytokines-dependent and insulin-dependent induction of
iNOS, decreased endothelial nitric oxide synthase (eNOS)
activity and reduced NO bioavailability [33–35]. Based on
our observation, it can be speculated that pathogenic over-
production of NO, as a putative underlying mechanism
involved in cardiovascular disease, may be prevented by a
higher intake of plant-derived L-arginine.
In the current study, mean intake of dietary L-arginine
was 4.0 ± 1.5 g/d and L-arginine intake was more from
grains and meats and less from nuts and legumes. Mean
intake of L-arginine in previous studies has been re-
ported 4 − 6 g/d [26, 36]. Recommended dietary allow-
ance has not yet been defined for L-arginine intake; soy
protein, peanuts, walnuts and fish meats are rich sources
while cereals and grains contain lower levels of L-arginine.
Different dietary patterns between populations, therefore,
may account for differences in mean intake of L-arginine.
Mean arginine intake for the US adults is reported to be
4.40 g/day, with 25 % of people consuming < 2.6 g/d [36].
Median L-arginine intake in an adult population, partici-
pants of the National Health Nutrition and Examination
Survey was also estimated to be 3.8 g/d. The highest level
(90th percentile) intake of L-arginine in our population
(6.1 g/d) was also within the range of previous reports
(4.5 − 7.5 g/d) [26].
The strengths of the current study were a population-
based prospective setting, and use of a validated FFQ to
assess regular dietary intake that provided an accurate
estimation for dietary L-arginine intake. Lack of data on
serum levels of L-arginine may be considered as an im-
portant limitation of this study.
Conclusion
In conclusion, our findings suggested a potential pro-
tective effect of plant-derived L-arginine intake in regu-
lation of blood pressure and prevention of CHD;
moreover, higher intake of L-arginine from animal
sources could be a dietary risk factor for development of
HTN and cardiovascular risk factors.
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